< Back to News

J.P. Morgan Healthcare Conference

Jan. 3, 2018

As the new year gets underway, the biotech sector continues its annual tradition of kicking things off in San Francisco at the J.P. Morgan Healthcare Conference. This is the biggest and most important gathering of companies, investors, the media, and pretty much anyone else who is even loosely associated with the sector. If you aren’t at JPM in January, you probably aren’t in biotech.

Here at the Cancer Immunotherapy ETF (Nasdaq: CNCR), we wanted to alert our investors about this event given its substantial significance. JPM is always newsworthy and often stock moving. 2018 is the 36th annual running and it officially takes place January 8-11. Our research team will be following events closely and listening for breaking news that might impact the cancer immunotherapy sector.

So what is JPM? And what are important things to focus on? There are three main things we recommend keeping in mind.

First, JPM is the place biotech companies go to do dealmaking. It is not uncommon for companies to announce new collaborations and partnerships around the conference. Additionally, business development teams and other industry executives will be hard at work on the ground scouting out potential new deals for 2018 and beyond.

Second, JPM is a time when many biotech companies seek to make a splash in the news. One thing we recommend is to look for announcements the night before the conference starts (January 7) because some companies like to get ahead of the news cycle by issuing press releases early. Others will wait to make announcements at various times throughout the conference itself.

Third, JPM is a place for companies to give public presentations where they discuss plans for the year ahead. These are great for investors to listen in on because you get a chance to hear straight from leadership about their priorities. Companies usually also provide a tangible list of catalysts or other guidance that you can use thereafter to track their progress.

Below is a schedule that shows what time CNCR Immunotherapy ETF (Nasdaq: CNCR) components are due to give a formal presentation at the conference. All times are Pacific, and the schedule is subject to change. If you are interested in hearing what a particular company has to say, we recommend visiting the investor relations section of its website because many will webcast the presentation and some also do the same for Q&A sessions that follow afterwards.

Monday, January 8
Cellectis (Nasdaq: CLLS) • 12:00 PM
Incyte Corporation (Nasdaq: INCY) • 1:30 PM
Gilead Sciences (Nasdaq: GILD) • 3:30 PM
Merck & Co., Inc. (NYSE: MRK) • 4:30 PM

Tuesday, January 9
bluebird bio, Inc. (Nasdaq: BLUE) • 7:30 AM
Bristol-Myers Squibb Co. (Nasdaq: BMY) • 10:00 AM
Nektar Therapeutics (Nasdaq: NKTR) • 11:00 AM
Atara Biotherapeutics (Nasdaq: ATRA) • 3:30 PM
Juno Therapeutics (Nasdaq: JUNO) • 4:00 PM
Five Prime Therapeutics (Nasdaq: FPRX) • 4:30 PM

Wednesday, January 10
Idera Pharmaceuticals (Nasdaq: IDRA) • 11:00 AM
Jounce Therapeutics (Nasdaq: JNCE) • 2:00 PM

Thursday, January 11
Dynavax Technologies Corporation (Nasdaq: DVAX) • 7:30 AM
Aduro Biotech (Nasdaq: ADRO) • 9:00 AM
ZIOPHARM Oncology (Nasdaq: ZIOP) • 10:00 AM
Newlink Genetics Corp (Nasdaq: NLNK) • 11:00 AM
MacroGenics, Inc. (Nasdaq: MGNX) • 11:00 AM

Thank you for your interest in the field of immunotherapy and support of the fund. We wish you healthy and prosperous 2018.

Opinions expressed are those of the author or Funds and are subject to change, are not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Fund holdings and allocations are subject to change at any time and should not be considered a recommendation to buy or sell any security.

View all holdings in the Loncar Cancer Immunotherapy ETF.

  • Loncar Funds
  • P.O Box 15072
  • Lenexa, KS 66285
  • +1 800-617-0004
  • Contact Us

CNCR Prospectus CHNA Prospectus

A basis point is a common unit of measure for interest rates and other percentages in finance. One basis point is equal to 1/100th of 1%, or 0.01% (0.0001).

The Loncar Cancer Immunotherapy Index is an index of 30 securities that have a strategic focus on the area of cancer immunotherapy, or harnessing the immune system to fight cancer. Quotes for the index can be found under the symbol “LCINDX” on the Bloomberg Professional service and other financial data providers. One may not directly invest in an index.

The Loncar China BioPharma Index is an index of 50 securities that have a strategic focus on advancing China’s biopharma industry. Quotes for the index can be found under the symbol “LCHINA” on the Bloomberg Professional service and other financial data providers. One may not directly invest in an index.

Holdings are subject to change.

The Hong Kong Stock Exchange (HKEX) is the primary stock exchange in the Hong Kong Special Administrative Region of China. Nasdaq is one of the primary stock exchanges in the United States.

Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus, which may be obtained at Read the prospectus carefully before investing.

Investing involves risk. Principal loss is possible. The fund may trade at a premium or discount to NAV. CNCR will invest in immunotherapy companies which are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company’s valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The costs associated with developing new drugs can be significant, and the results are unpredictable. The process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals with be obtained and maintained. The Fund may invest in foreign securities, which involve political, economic, currency risk, greater volatility, and differences in accounting methods. The Fund is non-diversified meaning it may concentrate its assets in fewer individual holdings than a diversified fund. Therefore, the Fund is more exposed to individual stock volatility than a diversified fund. The Fund invests in smaller companies, which may have more limited liquidity and greater volatility compared to larger companies. The Fund is not actively managed and may be affected by a general decline in market segments related to the index. The fund invests in securities included in, or representative of securities included in, the index, regardless of their investment merits. The performance of the fund may diverge from that of the Index and may experience tracking error to a greater extent than a fund that seeks to replicate an index. Shares are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns.

RISK FOR THE CHNA ETF: The biopharmaceutical industry in China is strictly regulated and changes in such regulations, including banning or limiting certain products, may have a material adverse effect on the operations, revenues, and profitability of Biopharma Companies. The laws and regulations applicable to the process of administrative approval of medicine and its production in China require entities producing biopharma products to comply strictly with certain standards and specifications promulgated by the government. Changes in currency exchange rates and the relative value of non-U.S. currencies will affect the value of the investment. Currency exchange rates can be very volatile and can change quickly and unpredictably. Investments in non-U.S. securities involve certain risks that may not be present with investments in U.S. securities. For example, investments in non-U.S. securities may be subject to risk of loss due to foreign currency fluctuations or to political or economic instability. Investments in non-U.S. securities also may be subject to withholding or other taxes and may be subject to additional trading, settlement, custodial, and operational risks. These and other factors can make investments in the Fund more volatile and potentially less liquid than other types of investments. To the extent the Fund invests a significant portion of its assets in the securities of companies of a single country or region, such as China, it is more likely to be impacted by events or conditions affecting that country or region. The Fund is a recently organized, non-diversified management investment company with no operating history. As a result, prospective investors have no track record or history on which to base their investment decision. The Fund is considered to be non-diversified, which means that it may invest more of its assets in the securities of a single issuer or a smaller number of issuers than if it were a diversified fund. The Fund is not actively managed and the Fund's sub-adviser would not sell shares of an equity security due to current or projected underperformance of a security, industry or sector, unless that security is removed from the Index or the selling of shares of that security is otherwise required upon a reconstitution of the Index in accordance with the Index methodology. To the extent the Fund invests more heavily in particular sectors of the economy, its performance will be especially sensitive to developments that significantly affect those sectors."

Diversification may not protect against market risk.

Exchange Traded Concepts, LLC serves as the investment advisor, and Vident Investment Advisory, LLC serves as a sub advisor to the fund. The Funds are distributed by Quasar Distributors, LLC, which is not affiliated with Exchange Traded Concepts, LLC or any of its affiliates.